Abstract 2124
Background
To explore the differences of MRI scan between pituitary adenomas and craniopharyngioma from MR image features to 3D based texture features.
Methods
A total number of 131 patients were introduced into this study (pituitary Adenomas =68; craniopharyngioma=63) with pre-surgery MRI image. Qualitative MR features and MRI texture features of lesion were evaluated using chi-square tests, Fisher exact test or Mann-Whitney U test. Multivariate logistic regression analyses were performed to access their ability as independent predictors. Accuracy measures were calculated substantially for the significant features.
Results
Five MRI features were suggested to be significantly different between pituitary adenomas and craniopharyngioma and one of them, cystic alteration could be considered as independent practical predictors. Three texture features from contrast enhanced images (Histo-Skewness, GLCM-Contrast and GLCM-Energy), two texture features from T2WI (Histo-Skewness and GLCM-Contrast) were found to be significantly related to discrimination between two types of diseases. Two texture features (Histo-Skewness and GLCM-Contrast) were found significantly to be in relation with cystic alteration.
Conclusions
Both of MRI image features and texture features, could make significant discrimination between pituitary adenoma and craniopharyngioma and represent practical diagnostic value; in addition, two type features associate with each other.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xuelei Ma.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1109 - First Canadian Interim Analysis from the Phase IIIb CompLEEment-1 Ribociclib + Letrozole HR+ HER2- Advanced Breast Cancer Trial
Presenter: Cristiano Ferrario
Session: Poster Display session 2
Resources:
Abstract
4401 - Real-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US
Presenter: Jonathan Kish
Session: Poster Display session 2
Resources:
Abstract
5876 - Palbociclib-Fulvestrant (PALBO-FUL) and Everolimus -Exemestane (EVE-EXE) for Second line Hormonal Treatment (HT) of Metastatic Breast Cancer (MBC) with Lobular Histology: a Propensity Score Matched Analysis of a Multicenter ‘Real-World’ Patients (pts) Series.
Presenter: Armando Orlandi
Session: Poster Display session 2
Resources:
Abstract
3587 - Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)
Presenter: E Dees
Session: Poster Display session 2
Resources:
Abstract
5696 - Final results of the STEM trial: SFX-01 in the Treatment and Evaluation of ER+ Her2- Metastatic breast cancer (mBC)
Presenter: Sacha Howell
Session: Poster Display session 2
Resources:
Abstract
1475 - Alpelisib (ALP) + Fulvestrant (FUL) in Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor-2–Negative (HER2–) Advanced Breast Cancer (ABC): Subgroup Analysis by Presence of Visceral Metastasis (VM) in the SOLAR-1 Trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
2549 - Phase 1 Dose Escalation Study of a Selective Androgen Receptor Modulator RAD140 in Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) Breast Cancer (BC)
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3787 - A Phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours
Presenter: Binghe Xu
Session: Poster Display session 2
Resources:
Abstract
4835 - Phase-I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
Presenter: Huiping Li
Session: Poster Display session 2
Resources:
Abstract
5083 - Phase 2 study of DHP107 (Liporaxel®, oral paclitaxel) in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)
Presenter: Jin-Hee Ahn
Session: Poster Display session 2
Resources:
Abstract